DUBLIN--(BUSINESS WIRE)--The "Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.
According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide based molecule, which is in the unknown stage for the treatment of acne vulgaris.
Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as sol-gel, in which silica on site forms a microcapsule shells and release drugs at site of action. The drug substance that is added during the sol-gel reaction is encapsulated, through which a core-shell structure is formed. Therefore, the contribution of advanced technologies for making targeted therapies is a key factor driving the growth of acne vulgaris pipeline therapeutics.
Report Segmentation
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
Key Topics Covered
Chapter 1. Research Background
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
Chapter 5. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)
Chapter 6. Clinical Trials Analysis
Chapter 7. Competitive Landscape
Chapter 8. Company Profiles
- Promius Pharma, LLC (subsidiary of Dr. Reddy's Laboratories Ltd.)
- Realm Therapeutics, Inc.
- Sienna Biopharmaceuticals, Inc.
- Sol-Gel Technologies Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/zffr78/global_acne?w=4
